Products
Ceftolozane was approved in the United States in 2014, in the EU in 2015, and in many countries in 2016 as an infusion preparation in fixed combination with tazobactam (Zerbaxa).
Structure and properties
Ceftolozane (C23H30N12O8S2, Mr = 666.7 g/mol) is present in the drug as ceftolozane sulfate.
Effects
Ceftolozane (ATC J01DI54) has bactericidal properties. The effects are due to inhibition of bacterial cell wall formation. Tazobactam is a beta-lactamase inhibitor that reverses resistance to the antibiotic. The active ingredients have short half-lives: Ceftolozane 3 hours, tazobactam 1 hour.
Indications
For treatment of bacterial infectious diseases:
- Complicated intra-abdominal infections, in combination with metronidazole.
- Complicated urinary tract infections, including pyelonephritis.
Dosage
According to the professional information. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity to the active ingredients or excipients.
- Hypersensitivity to cephalosporins
- Severe hypersensitivity to other beta-lactam antibiotics.
For complete precautions, see the drug label.
Interactions
OAT1 or OAT3 inhibitors such as probenecid may increase plasma concentrations of tazobactam.
Adverse effects
The most common potential adverse effects include nausea, diarrhea, headache, and fever.